Recruiting
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637· Phase 3· AstraZeneca· Source
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666· Phase 3· AstraZeneca· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978· Phase 3· AstraZeneca· Source
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597· Phase 4· AstraZeneca· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658· Phase 2· AstraZeneca· Source
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· Phase 3· AstraZeneca· Source
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782· Phase 1/2· AstraZeneca· Source
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· Phase 3· AstraZeneca· Source
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161· Phase 1/2· AstraZeneca· Source
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646· Phase 1/2· Alexion Pharmaceuticals, Inc.· Source
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457· Phase 1/2· AstraZeneca· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024· Phase 2· AstraZeneca· Source
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665· Phase 3· AstraZeneca· Source
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097· Phase 3· AstraZeneca· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Active, not recruiting
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099· Phase 2· AstraZeneca· Source
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· Phase 3· AstraZeneca· Source
Contact: AstraZeneca Breast Cancer Study Locator Service
Active, not recruiting
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171· Phase 1· Arcus Biosciences, Inc.· Source
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861· Phase 3· DalCor Pharmaceuticals· Source
Contact: David Kallend, MBBS
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589· Phase 3· AstraZeneca· Source
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234· Phase 1/2· AstraZeneca· Source
Active, not recruiting
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644· Phase 3· AstraZeneca· Source
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168· Phase 1/2· AstraZeneca· Source
Active, not recruiting
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· Phase 3· AstraZeneca· Source
Active, not recruiting
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141· Phase 1· Arcus Biosciences, Inc.· Source
Contact: Medical Director
Active, not recruiting
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440· Phase 1/2· AstraZeneca· Source
Active, not recruiting
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· Phase 3· AstraZeneca· Source
Active, not recruiting
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895· Phase 3· AstraZeneca· Source
Active, not recruiting
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663· Phase 3· AstraZeneca· Source
Active, not recruiting
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715· Phase 3· AstraZeneca· Source
Active, not recruiting
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT04504825· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425· Phase 3· AstraZeneca· Source
Active, not recruiting
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· Phase 3· AstraZeneca· Source
Active, not recruiting
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123· Phase 3· AstraZeneca· Source
Active, not recruiting
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154· Phase 3· AstraZeneca· Source
Active, not recruiting
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643· Phase 3· AstraZeneca· Source
Active, not recruiting
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957· Phase 3· AstraZeneca· Source
Active, not recruiting
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677· Phase 3· AstraZeneca· Source
Active, not recruiting
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820· Phase 3· AstraZeneca· Source
Showing 50 of 55.